Hematopoetic

造血

• 批准号: 8181092
• 负责人: Robert S Negrin
• 金额: $ 1.74万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-09-15 至 2015-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8181092
• 关键词: Acute; Allogenic; Animal Model; Arvin; Autoimmune Diseases; Autologous; Basic Science; Biological; Biological Models; Biology; Blood specimen; Bone Marrow Transplantation; Cancer Center; Cell Transplantation; Cells; Cellular biology; Cities; Clinic; Clinical; Clinical Research; Clinical Trials Network; Collaborations; Commit; Complex; Complication; Defect; Disease; Drug Combinations; Dysmyelopoietic Syndromes; Eastern Cooperative Oncology Group; Engraftment; Enrollment; Environment; Fred Hutchinson Cancer Research Center; Genetic; Goals; Graft-Versus-Tumor Induction; Hematologic Neoplasms; Hematopoietic; Hematopoietic stem cells; Hodgkin Disease; Human; Humoral Immunities; Image; Immune; Immune response; Immunity; Immunology; Immunosuppressive Agents; Investigation; Killer Cells; Laboratories; Laboratory Research; Life; Malignant Neoplasms; Medical center; Methodology; Minor; Modeling; Morbidity - disease rate; Multiple Myeloma; Mus; Myeloproliferative disease; Natural regeneration; Non-Hodgkin' s Lymphoma; Opportunistic Infections; Organ Transplantation; Outcome; Patients; Phase; Phase III Clinical Trials; Population; Progenitor Cell Engraftment; Reaction; Recurrent disease; Research; Research Personnel; Risk; Sampling; Solid; Southwest Oncology Group; Staging; Stem Cell Development; Stem cells; T-Cell Development; T-Lymphocyte; Techniques; Technology; Testing; Therapeutic; Tissues; Translating; Translational Research; Translations; Transplantation; Transplantation Tolerance; Universities; Work; base; cancer cell; chronic leukemia; clinical application; clinical care; cytokine; disorder risk; graft vs host disease; improved; innovation; insight; mortality; novel; pathogen; preclinical study; progenitor; programs; reconstitution; response; stem; stem cell biology

The research program in Hematopoietic Cell Transplantation and Immune Reconstitution (Program 08) focuses on elucidating basic biological principles of hematopoietic cell transplantation (HCT) and furthering the treatment of patients with life-threatening hematologic malignancies. The major theme of the Program is the discovery of immunology and stem cell biology principles that can be translated into innovative HCT based therapies. Our goals are: ¿ To gain fundamental insights into the cellular basis of hematopoietic stem and progenitor cell engraftment. ¿ To explore the basic biology of graft-versus-host disease (GVHD) and graft-versus-tumor (GVT) reactions in the context of transplantation. ¿ To develop strategies to improve immune reconstitution. ¿ To translate promising concepts developed in pre-clinical studies to the clinic. Using a highly interactive group of investigators with a rich array of animal models incorporating the latest techniques of cell biology, imaging, genetics and array technologies we will explore in animal models and in patients the biological principles that govern these immune-based reactions and develop strategies to improve outcomes for our patients. These concepts could also have an impact on a variety of other clinical situations, such as for the treatment of autoimmune disorders and induction of solid organ transplantation tolerance. Using the principles of translational science whereby model systems are developed in the laboratory and concepts are tested in the clinic in a bi-directional fashion, analyzing patients' samples will allow us to test important concepts of HCT and follow critical leads established in research laboratories to the treatment of patients with hematologic disorders.

造血细胞移植与免疫重建研究计划（08计划） 重点阐述造血细胞移植（HCT）的基本生物学原理， 进一步治疗危及生命的血液恶性肿瘤患者。的重大主题 该计划是免疫学和干细胞生物学原理的发现，可以转化为 基于HCT的创新疗法。我们的目标是： <$获得造血干细胞和祖细胞的细胞基础的基本见解 移植 探讨移植物抗宿主病（GVHD）和移植物抗肿瘤（GVT）的基础生物学 移植过程中的反应。 开发策略以改善免疫重建。 将临床前研究中开发的有前途的概念转化为临床。 使用一个高度互动的研究小组，使用丰富的动物模型， 最新的细胞生物学技术，成像，遗传学和阵列技术，我们将在动物中探索 模型和患者的生物学原则，支配这些免疫反应，并发展 改善患者预后的策略。这些概念也可能对各种 其他临床情况下，如用于治疗自身免疫性疾病和诱导固体 器官移植耐受利用转化科学的原理， 在实验室开发和概念在临床测试中以双向的方式，分析 患者的样本将使我们能够测试HCT的重要概念，并遵循 研究实验室来治疗血液病患者。